![Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ... Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ...](https://www.thelancet.com/cms/attachment/667fb1ef-eea1-4451-89ae-8d139b42b5a0/gr1.gif)
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ...
![Ioannis FLESSAS | Consultant | MD, MSc, PhD, FEBS, FACS | Henry Dunant Hospital, Athens | C Breast Clinic | Research profile Ioannis FLESSAS | Consultant | MD, MSc, PhD, FEBS, FACS | Henry Dunant Hospital, Athens | C Breast Clinic | Research profile](https://i1.rgstatic.net/ii/profile.image/272470099886117-1441973342963_Q512/Ioannis-Flessas.jpg)
Ioannis FLESSAS | Consultant | MD, MSc, PhD, FEBS, FACS | Henry Dunant Hospital, Athens | C Breast Clinic | Research profile
![Han WONG | Consultant Medical Oncologist | MB ChB, PhD, FRCP | Cambridge University Hospitals NHS Foundation Trust, Cambridge | Addenbrooke's Hospital | Research profile Han WONG | Consultant Medical Oncologist | MB ChB, PhD, FRCP | Cambridge University Hospitals NHS Foundation Trust, Cambridge | Addenbrooke's Hospital | Research profile](https://i1.rgstatic.net/ii/profile.image/11431281189206275-1694962428594_Q512/Han-Wong-3.jpg)
Han WONG | Consultant Medical Oncologist | MB ChB, PhD, FRCP | Cambridge University Hospitals NHS Foundation Trust, Cambridge | Addenbrooke's Hospital | Research profile
![Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays | npj Precision Oncology Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays | npj Precision Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41698-023-00442-4/MediaObjects/41698_2023_442_Fig1_HTML.png)
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays | npj Precision Oncology
![Sarah HILBORNE | Senior Research Nurse | PG Cert Health Studies | University of Cambridge, Cambridge | Cam | Department of Medicine | Research profile Sarah HILBORNE | Senior Research Nurse | PG Cert Health Studies | University of Cambridge, Cambridge | Cam | Department of Medicine | Research profile](https://i1.rgstatic.net/ii/profile.image/818192796639234-1572083772690_Q512/Sarah-Hilborne.jpg)